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Abstract
Objective: Patients with non-functioning pituitary adenomas exhibit high morbidity 
and mortality rates. Growth hormone deficiency and high doses of glucocorticoid 
substitution therapy have been identified as corresponding risk factors. Interestingly, 
high levels of endogenous cortisol in, e.g., patients with post-traumatic stress disorder or 
patients with Cushing’s disease have been linked to shorter telomere length. Telomeres 
are noncoding DNA regions located at the end of chromosomes consisting of repetitive 
DNA sequences which shorten with aging and hereby determine cell survival. Therefore, 
telomere length can serve as a predictor for the onset of disease and mortality in some 
endocrine disorders (e.g., Cushing’s disease).
Design/methods: Here, we examine telomere length from blood in patients (n = 115) 
with non-functioning pituitary adenomas (NFPA) in a cross-sectional case–control 
(n = 106, age-, gender-matched) study using qPCR. Linear regression models were used to 
identify independent predictors of telomere length.
Results: We show that patients with NFPA exhibited shorter telomeres than controls. No 
significant association of indices of growth hormone deficiency (IGF-1-level-SDS, years 
of unsubstituted growth hormone deficiency etc.) with telomere length was detected. 
Interestingly, linear regression analysis showed that hydrocortisone replacement dosage 
in patients with adrenal insufficiency (n = 52) was a significant predictor for shorter 
telomere length (β = 0.377; P = 0.018) independent of potential confounders (gender, age, 
BMI, arterial hypertension, systolic blood pressure, number of antihypertensive drugs, 
total leukocyte count, waist-to-hip ratio, waist circumference, diabetes mellitus type 2, 
HbA1c, current statin use). Median split analysis revealed that higher hydrocortisone 
intake (>20 mg) was associated with significantly shorter telomeres.
Conclusion: These observations strengthen the importance of adjusted glucocorticoid 
treatment in NFPA patients with respect to morbidity and mortality rates.
Introduction
Telomeres are noncoding DNA regions located at the end 
of chromosomes consisting of repetitive DNA sequences. 
Their primary purpose is to protect the chromosome from 
degradation processes and from loss of genetic material 
during cell division. When telomeres reach a critical short 
length, cell division is terminated and the corresponding 
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cells undergo apoptosis (1). Telomerase, the key enzyme 
relevant for telomeric DNA synthesis and maintenance of 
telomere length (TL) is differently expressed in different 
tissue types and its expression levels depend on the status 
of the cell itself (2, 3, 4, 5). Differential telomerase activity 
is likely to account for differences in TL in distinct cell 
types of the human body. Nevertheless, blood TL is used 
as an easily accessible and well-established surrogate tissue 
for TL in other cells of the entire organism, especially 
when analyzing systemic effects of chronic diseases (6).
Typically, TL shortens with aging and shorter 
telomeres seem to be associated with age-related disease 
(7) as well as inflammatory states, cardiovascular disease, 
diabetes mellitus type 2 (DM2), poor lipid profile and high 
blood pressure (8, 9, 10). Furthermore, a variety of factors 
such as epigenetic and environmental factors, including 
life style habits such as diet or smoking can influence and 
modulate telomerase activity (1).
Apart from the aforementioned conditions, another 
influential factor concerning TLs is hormones (11). 
Currently, pituitary tumors such as somatotropic and 
corticotropic adenomas resulting in hormone excess 
conditions such as acromegaly (12, 13) and Cushing’s 
syndrome (13) have been associated with accelerated 
telomere shortening (14, 15), suggesting that TL length 
might be linked to the increased morbidity and mortality 
observed for both diseases (16, 17).
To the best of our knowledge, studies examining the 
TL in patients with non-functioning pituitary adenomas 
(NFPA), characterized by a high incidence of endocrine 
deficiencies, have not been conducted. However, taking 
into account that this patient group exhibits an increased 
morbidity and mortality (18) and the precise underlying 
mechanisms of this phenomenon have not been fully 
elucidated so far, TL studies in these patients could be very 
relevant. The higher morbidity and mortality in patients 
with NFPA has been attributed to cardiorespiratory and 
infectious diseases. Even though there is no consensus on 
predictive factors of mortality, high doses of glucocorticoid 
substitution therapy and older age at diagnosis are the 
most consistently identified risk factors associated with 
increased morbidity and mortality (18, 19). In addition, 
growth hormone deficiency (GHD) has been linked to 
mortality, although due to the retrospective character of 
these studies, there is still a debate if this relationship is 
causal (20, 21).
In the current study, we examined whether TL is 
shorter in patients with NFPA compared to controls and 
if so, how hormonal deficiencies and their replacement 
respectively affect TL.
Materials and methods
Patients and control group
We included 115 patients with NFPA treated in the 
Neuroendocrinology Unit of the Max Planck Institute of 
Psychiatry in Munich. Samples were retrieved from the 
biobank of the Network of Excellence for Neuroendocrine 
Tumors Munich (NeoExNET). All patients gave written 
informed consent and the study was approved by the 
Ethical Review Board of the Ludwig Maximilian University 
of Munich. The diagnosis of NFPA was based on clinical 
and laboratory findings as well as imaging studies and 
was confirmed by the pathological examination in 
patients who had undergone surgery. Clinical data, 
history of medication and comorbidities were collected 
retrospectively from patients’ charts (Table 1).
Evaluation of pituitary function was based on basal 
measurements of thyroid-stimulating hormone (TSH), free 
thyroxine (FT4), free triiodothyronine (FT3), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH) and 
total testosterone (in men) or estradiol (in women). Adrenal 
insufficiency was documented by ACTH stimulation test or 
insulin-tolerance test, whereas GHD by insulin-tolerance test 
or GHRH-arginine test. Additional parameters were assessed 
after an overnight fasting between 8:00 and 11:30 h using 
routine clinical methods at the local laboratory of the Max 
Planck Institute of Psychiatry. Insulin-like growth factor 1 
(IGF-1) and growth hormone (GH) were measured on the 
IMMULITE 2000 analyzer (Siemens). In women in the fertile 
age range, secondary hypogonadism was defined as the 
combination of low LH/FSH with secondary amenorrhea 
for at least 1  year. In women in the postmenopausal age 
range, secondary hypogonadism was documented when 
LH/FSH were inappropriately low for the postmenopausal 
age. In men, secondary hypogonadism was defined as 
a low testosterone level with an inappropriately low 
LH/FSH. Secondary hypothyroidism was defined as low FT4 
combined with an inappropriately low serum TSH. Patients 
with adrenal insufficiency were treated with conventional 
hydrocortisone usually divided into 2–3 doses per day. 
Secondary hypothyroidism was treated with levothyroxine. 
Gonadotropic insufficiency was treated with testosterone in 
men (in form of transdermal gel or intramuscular injections) 
and with estrogen/progesterone replacement in women or 
in case of past hysterectomy with estradiol only. GHD was 
treated with recombinant human GH.
One hundred six controls were selected from a 
large control group previously recruited for the scope of 
another study (signed informed consent for the genetic 
analysis was also obtained from the controls) (22) and 
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-18-0362
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/21/2019 11:11:12AM
via free access
A P Athanasoulia-Kaspar, 
M K Auer et al.
Telomeres in hypopituitarism 12197:11
were matched for gender and age; the controls did not 
differ from NFPA patients regarding smoking status that 
is known to affect TL (Table 1). Furthermore, the presence 
of anxiety and affective disorders was excluded using the 
Composite International Diagnostic Screener. Metabolic 
comorbidities such as hypercholesterinemia, arterial 
hypertension and DM2 were provided by self-report. For 
nine patients, no corresponding matching partner could 
be identified explaining unequal group sizes.
Anthropometric parameters (weight, height, BMI 
and waist-to-hip ratio) were documented for the 
majority of the subjects. Hypertension was defined 
as systolic blood pressure >140 mmHg or diastolic 
blood pressure >90 mmHg or previous treatment with 
antihypertensive medications. DM2 was confirmed 
by fasting glucose >126 mg/dL in two consecutive 
measurements or glucose 2 h after an oral tolerance test 
>200 mg/dL or previous treatment with antidiabetic 
medications. Recorded biochemical parameters of 
lipid metabolism were total cholesterol, low-density 
lipoprotein (LDL), high-density lipoprotein (HDL) and 
triglycerides. Statin medication was noted (Table 1).
TL measurement
TL was assessed in genomic DNA (gDNA), derived from 
EDTA whole blood. Blood samples were kept at 4°C 
after blood draw. gDNA from patient and control blood 
samples was extracted using the Gentra Puregene Blood 
Kit (Qiagen) and stored at 4°C. Samples were diluted to 
a concentration of 50 ng/µL and TL was measured by 
qPCR using a LightCycler FastStart DNA Master SYBR 
Green kit (Roche Diagnostics) on a LightCycler 96 
Instrument (Roche Diagnostics). PCR reactions were 
run as quadruplicates, split between two different PCR 
plates with duplicates of each sample on every plate, 
Table 1 Clinical and biochemical characteristics of NFPA patients and controls.
NPFA patients (n = 115) Controls (n = 106)
P
N (%)
Mean SDS
N (%)
Mean SDSValid Missing Valid Missing
Age (years) 115 0 57.7 16.76 106 0 58 14.79 NS
Gender (male) 58 (50.4) 0 n.a. n.a. 58 0 n.a. n.a. NS
Body mass index (kg/m2) 115 0 28.28 5.28 104 0 26.5 4.2 NS
Current smokers 14 10* n.a. n.a. 22 6** n.a. n.a. NS
Macroadenoma 111 (96.5) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Pituitary surgery 106 (92.2) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Radiotherapy 17 (14.7) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Diabetes mellitus type 2 12 (10.4) 0 n.a. n.a. 2 (1.9) 2 n.a. n.a. 0.011
Fasting glucose (mg/dL) 100 15 86.5 15.63 n.a. n.a. n.a. n.a. n.a.
HbA1c (%) 94 21 5.53 0.64 n.a. n.a. n.a. n.a. n.a.
Pituitary insufficiency of any axis 90 (78.3) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
GHD 79 (68.7) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
GHD under substitution 27 (34) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Gonadotropic insufficiency 51 (44.3) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Hypothyroidism 67 (58.3) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Adrenal insufficiency (all under 
substitution with hydrocortisone)
52 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Diabetes insipidus 18 (15.7) 0 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Arterial hypertension 45 (39.1) 0 n.a. n.a. 18 (16.9) 2 n.a. n.a. 0.001
Systolic blood pressure (mmHg) 108 7 135.74 20.44 n.a. n.a. n.a. n.a. n.a.
Diastolic blood pressure (mmHg) 108 7 84.95 13.35 n.a. n.a. n.a. n.a. n.a.
Waist circumference (cm) 85 30 95.69 13.23 n.a. n.a. n.a. n.a. n.a.
Hip circumference (cm) 78 37 105.5 18.72 n.a. n.a. n.a. n.a. n.a.
Waist-to-hip-ratio 67 48 1.03 1.08 n.a. n.a. n.a. n.a. n.a.
Hypercholesterolemia/statin use 31 (27.0) 0 n.a. n.a. 14 (13.2) 2 n.a. n.a. 0.016
Triglycerides (mg/dL) 98 17 141.04 80.1 n.a. n.a. n.a. n.a. n.a.
Total cholesterol (mg/dL) 110 5 209.26 40.69 n.a. n.a. n.a. n.a. n.a.
HDL cholesterol (mg/dL) 95 20 59.35 18.65 n.a. n.a. n.a. n.a. n.a.
LDL cholesterol (mg/dL) 94 21 138.95 35.05 n.a. n.a. n.a. n.a. n.a.
White blood cell count (×109/L) 108 7 6.24 1.35 n.a. n.a. n.a. n.a. n.a.
IGF-1-SDS (ng/mL) 100 15 136.75 72.99 n.a. n.a. n.a. n.a. n.a.
GHD, growth hormone deficiency; n.a., non-applicable; NS, non-significant.
*In the NFPA group, 14 current smokers, 32 former smokers and 59 did never smoke; **In the control group, 22 current smokers, 34 former smokers and 
44 did never smoke.
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
https://doi.org/10.1530/EC-18-0362
https://ec.bioscientifica.com © 2018 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 11/21/2019 11:11:12AM
via free access
A P Athanasoulia-Kaspar, 
M K Auer et al.
Telomeres in hypopituitarism 12207:11
using 1 µL diluted gDNA per 10 µL PCR reaction. The 
following primers were used in a final concentration of 
0.25 µM, tel1b, 5′-CGGTTTGTTTGGGTTTGGGTTTGGG 
TTTGGGTTTGGGTT-3′ and tel2b, 5′-GGCTTGCCTTAC 
CCTTACCCTTACCCTTACCCT TACCCT-3′ for measuring 
TL, and 36B4u, 5′-CAGCAAGTGGGAAGGTGTAATCC-3′ 
and 36B4d, 5′-CCCATTCTATCATCAACGGGTACAA-3′, 
for the single-copy gene 36B4/RPLP0 (encoding the 60S 
acidic ribosomal phosphoprotein P0) as housekeeping 
primers (20). PCR conditions for telomere measurements 
were 10 min at 95°C for activation of the polymerase, 
followed by 30 amplification cycles of 95°C for 5 s, 56°C 
for 10 s and 72°C for 60 s, and for the housekeeper: 10 min 
at 95°C for activation of the polymerase, followed by 40 
amplification cycles of 95°C for 5 s, 58°C for 10 s and 72°C 
for 40 s. To minimize batch effects, four samples of each 
batch were measured again together with the next batch. 
At the end of the entire experiment, an independent 
‘calibrator plate’ containing four samples of each batch 
was run as well. First, mean Ct values for telomere and 
housekeeper measurements were normalized by their 
mean difference between repeated measurements on 
consecutive plates and on the ‘calibrator plate’. Ct values 
for telomeres were further corrected with the housekeeper 
results and have been logarithmized (log2) (23).
Measurement of TL is not trivial. Multiple studies have 
pointed to a pleiotropy of confounding factors, including 
sample storage and extraction methods (24, 25). We have 
made sure that all blood samples and resulting gDNA were 
handled, extracted and stored exactly in the same way. To 
test whether gDNA samples were of sufficiently consistent 
quality for telomere measurements, we determined 
telomere qPCR values for a subset of samples (n = 64) 
and correlated them with the age of the subjects. In line 
with previous reports of decreasing TL with age (1, 3), 
we found the TL to be highly negatively correlated with 
age (r2 = 0.45, P ≤ 0.001, Fig. 1), indicative of consistently 
suitable sample quality allowing us to obtain reliable 
qPCR results.
Statistical methods
Statistical analysis was conducted using SPSS 21.0. 
for Windows software (SPSS Inc). Demographic data 
are presented by means and standard deviations and 
frequencies. Data were examined for normality using 
histograms and, if skewed, were normalized by log 
transformation for further testing procedures. Descriptive 
statistics are presented as untransformed mean values 
for simplicity. A chi-square test was performed for 
categorical variables. Fisher exact test was performed 
when appropriate. Univariate linear regression analysis 
was used as appropriate to estimate linear association 
between potential confounders with TL (age, gender, 
BMI, current smoking status (smoker vs no smoker), DM2 
(yes/no), fasting glucose, HbA1c, arterial hypertension 
(yes/no), number of antihypertensive drugs, systolic 
and diastolic blood pressure, waist-to-hip-ratio, waist 
circumference, total leukocyte count, time since diagnosis 
(in months), pituitary insufficiency of any axis, overt 
sex steroid deficiency (unsubstituted gonadotropic 
deficiency + menopausal status not receiving replacement 
therapy) (yes/no), hypothyroidism, overt GHD (substituted 
GHD and unsubstituted GHD) (yes/no), growth hormone 
dose, IGF-1-SDS, adrenal insufficiency (yes/no), daily 
total hydrocortisone dose, diabetes insipidus (yes/no), 
triglycerides, current statin use (yes/no), total cholesterol 
and HDL/LDL cholesterol) (Table 2). Analysis of covariance 
(ANCOVA) was performed to evaluate TL between groups 
after adjustment for BMI, DM2, arterial hypertension and 
hypercholesterinemia.
A two-block linear regression analysis was carried out 
to assess the contribution of different variables to TL. For 
regression analysis, multiple imputation was used to fill in 
missing values based on the confirmation that the missing 
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Figure 1
Shorter telomere length in NFPA patients. Correlation of adjusted pPCR 
values (Ct) with age in NFPA patients (n = 115) and controls (n = 106). Note, 
higher Cts are indicative of shorter telomeres. Pearson correlation: r = 0.404, 
P ≤ 0.001 (NFPA) and r = 0.282, P = 0.003 (controls). Ct, threshold cycle.
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pattern was completely at random (26). Five complete 
datasets were created, to compensate for the uncertainty 
caused by missing values (27). Subsequently, linear 
regression modeling was performed on each dataset, and 
the regression coefficients of the five models were pooled.
Block 1 included gender, age and BMI. A forced entry 
method was used for block 1 as we deemed inclusion 
of these variables, according to earlier studies, a basic 
requirement for our model. In the second block, we added 
those variables that had been identified in univariate 
regression analysis as showing a linear correlation at least 
on trend level (P < 0.1) with TL. All statistical tests were 
performed with α ≤ 0.05 (two-tailed).
Results
The clinical characteristics of the patients with NFPA and 
controls are presented in Table 1. In the NFPA group, 111 
patients presented with a macroadenoma and 106 had 
undergone surgery at least once. The mean time since 
first diagnosis was 132.8 months (± 86.88). A total of 90 
patients (78.3%) presented with pituitary insufficiency 
of at least one axis (including adrenal, gonadotropic, 
somatotropic and thyrotropic insufficiency or diabetes 
insipidus). Herein, 79 (68.7%) presented with GHD and 
34% of them were under substitution with recombinant 
human GH; 51 (44.3%) suffered from gonadotropic 
insufficiency and 67 (58.3%) were hypothyroid (all on 
levothyroxine replacement), whereas 18 presented 
with diabetes insipidus and were under substitution 
with desmopressin and 52 patients were diagnosed with 
adrenal insufficiency and were under substitution with 
conventional hydrocortisone.
To investigate whether patients with NFPA exhibit 
shorter telomeres, we first compared them with age- 
and gender-matched controls. There were no statistical 
differences between the two groups regarding ratio 
of smoking or in terms of BMI compared to controls 
(28.28 kg/m2 ± 5.28 vs 26.5 ± 4.2 kg/m2, P = 0.07, Table  1). 
Table 2 Univariate correlation analysis of telomere length with clinical and biochemical characteristics of NFPA patients and 
controls.
Telomere length
NFPA (N = 114) Controls (N = 106)
β P N β P N
Age 0.17* <0.001* 114* 0.08* 0.003* 106*
BMI 0.017 0.167 114 0.012 0.092 106
Gender 0.000 0.896 114 0.005 0.467 106
Current smoking status 0.003 0.556 104 0.001 0.739 100
Diabetes mellitus type 2 0.040* 0.032* 114* 0.015 0.232 104
Fasting glucose 0.020 0.13 99 NA NA NA
HbA1c 0.051* 0.04* 83* NA NA NA
Arterial hypertension 0.120* <0.001* 114* 0.000 0.965 104
Number of antihypertensive drugs 0.130* <0.001* 114* NA NA NA
Systolic blood pressure 0.060* 0.009* 107* NA NA NA
Diastolic blood pressure 0.006 0.424 107 NA NA NA
Waist-to-hip ratio 0.017 0.294 66 NA NA NA
Waist circumference 0.030* 0.09* 84* NA NA NA
Total leukocyte count 0.050* 0.03* 107* NA NA NA
Time since diagnosis 0.017 0.255 79 NA NA NA
Pituitary insufficiency of any axis 0.014 0.202 114 NA NA NA
Overt sex steroid deficiency 0.012* 0.178* 114* NA NA NA
Hypothyroidism 0.005 0.472 114 NA NA NA
Overt growth hormone deficiency 0.006 0.412 114 NA NA NA
Growth hormone dose 0.020 0.368 36 NA NA NA
IGF-1-SDS 0.004 0.526 99 NA NA NA
Adrenal insufficiency 0.001 0.731 114 NA NA NA
Daily total hydrocortisone dose 0.060* 0.091* 52* NA NA NA
Diabetes insipidus 0.003 0.551 114 NA NA NA
Triglycerides 0.008 0.395 97 NA NA NA
Current statin use 0.030* 0.079* 114* NA NA NA
Total cholesterol 0.007 0.388 109 NA NA NA
HDL cholesterol 0.003 0.580 94 NA NA NA
LDL cholesterol 0.002 0.662 93 NA NA NA
*Parameters which showed a linear correlation at least on trend level (P < 0.1) with telomere length.
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However, components of the metabolic syndrome such 
as hypercholesterolemia (27 vs 13.2%; P = 0.016), arterial 
hypertension (39.1 vs 16.3%, P = 0.001) and DM2 (10.4 
vs 1.9%, P = 0.011) were more common in NFPA patients 
than in the control population.
We found that patients with NFPA had shorter 
telomeres compared to controls (CtTrans1.65 ± 0.22 
vs CtTrans1.56 ± 0.21, P = 0.01). Note, typically, longer 
telomere templates contain more repeat regions and 
will create more PCR product in a shorter time, and 
therefore, lead to lower Ct values in qPCR applications. 
This difference remained significant when adjusting for 
hypercholesterolemia, arterial hypertension and DM2 by 
ANCOVA (F = 5.898, df = 3, P = 0.001).
We conducted an explorative univariate regression 
analysis to define which variables could influence the TL 
and found that the following parameters showed a linear 
correlation at least on trend level (P < 0.1) with TL: age, DM2, 
HbA1c, arterial hypertension, number of antihypertensive 
drugs, systolic blood pressure, waist circumference, total 
leukocyte count, daily total hydrocortisone dose, current 
statin use (Table 2). In controls, with regard to available 
variables, there was only a significant correlation with 
age. As expected, there was a positive correlation of age 
with shorter TL in NFPA patients (β = 0.17; P ≤ 0.001) and 
controls (β = 0.08, P = 0.003). As indicated by the higher 
β-coefficient, telomere shortening seemed to be accelerated 
in the NFPA group in comparison to controls.
Parameters like BMI, gender, current smoking status, 
fasting glucose, diastolic blood pressure, waist-to-hip ratio, 
time since diagnosis, pituitary insufficiency of any axis, 
HbA1c, overt sex steroid deficiency, hypothyroidism, overt 
GHD, growth hormone dose, IGF-1, adrenal insufficiency, 
diabetes insipidus, triglycerides levels, total cholesterol, 
LDL and HDL cholesterol were not significant and were 
not included in the regression. The fully adjusted model 
(Block 2) explained 42.9% of the variance in TL according 
to the adjusted R2 (Table 3). In the model, the ‘best-fitting’ 
variables were BMI (β = −0.429; P = 0.015), number of 
antihypertensive drugs (β = 0.404; P = 0.014) and total HC 
dosage (β = 0.377; P = 0.018).
Since we identified ‘daily total hydrocortisone dose’ 
as a significant independent factor of variance in the 
regression analysis, we compared patients with adrenal 
insufficiency with patients with intact corticotropic axis 
(Fig. 2). We found that there was no difference regarding 
TL between patients with and without hydrocortisone 
substitution. The two groups differ only in terms of basal 
glucose levels and diastolic blood pressure, but not in terms 
of BMI, age, white blood cell count, waist circumference 
or other parameters such as triglycerides, total cholesterol, 
HDL or LDL cholesterol or systolic blood pressure. There 
was no difference between TL of patients with intact GH 
axis and those with GHD under GH substitution and 
those with GHD and no treatment of growth hormone 
(data not shown).
To investigate the effect of hydrocortisone with a 
focused approach, we conducted a median split analysis 
in the group of patients with hydrocortisone substitution 
and we divided patients into two groups, i.e., one with 
patients who received a total daily hydrocortisone 
substitution of 20 mg or less (Group 1 − G1 – n = 43, mean 
daily hydrocortisone dose 17.39 ± 3.96 mg) and the other 
one with patients who received a dose higher than 
20 mg (Group 2 − G2 − n = 9, mean daily hydrocortisone 
dose 27.78 ± 5.07 mg). We found that patients in G2 
on the higher hydrocortisone dose exhibited shorter 
telomeres than in group 1 (G1 CtTrans 1.63 ± 0.21 vs G2 
CtTrans 1.82 ± 0.197, P = 0.012). Groups did not differ in 
fasting blood glucose levels, HbA1c, BMI, white blood cell 
count, waist-to-hip ratio, waist circumference, age, total 
cholesterol, HDL/LDL cholesterol, triglycerides, IGF-1-
SDS, diastolic or systolic blood pressure.
Discussion
Our initial hypothesis was that patients with NFPA exhibit 
accelerated telomere shortening due to different pituitary 
insufficiencies. To test this hypothesis, we compared 
TL of NFPA patients and controls and examined the 
influence of different pituitary insufficiencies including 
adrenal, gonadotropic and somatotropic. Indeed, we 
could demonstrate that patients with NFPA exhibit shorter 
telomeres than controls and that telomere shortening 
per year of age seems to be accelerated in these patients. 
Interestingly, among patients with pituitary insufficiencies, 
there was a clear association of higher hydrocortisone 
doses with shorter TL. To the best of our knowledge, this is 
the first study to evaluate TL in patients with NFPA.
TL serves as an early predictor of disease onset and 
all-cause mortality for numerous diseases. Several studies 
suggest that shorter telomeres are found in patients that 
exhibit a higher all-cause mortality and TLs appear to 
reflect the ‘ability to survive’ (28). Furthermore, short TLs 
may also be a risk factor for cardiovascular diseases as it is 
associated with metabolic disturbances such as high blood 
glucose and greater abdominal obesity, poor lipid profile, 
high systolic blood pressure, higher fasting glucose levels 
and smoking (29).
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Patients with NFPA have higher mortality rates 
in comparison to the general population, although 
studies assessing mortality in these patients are limited. 
Standardized mortality ratios have been reported to 
be significantly increased in female NFPA patients as 
compared to male NFPA patients as well as in patients 
treated with radiotherapy; they are mostly attributed 
to infectious and cardio/cerebrovascular diseases (30, 
31). The role of age at diagnosis as a predictive factor 
of mortality is discussed controversially. Whereas some 
studies suggest a positive correlation of age at diagnosis 
and mortality (32, 33), Olsson et al. (2015) come to the 
opposite conclusion that age of 40 years and earlier is a 
predictor of mortality (31).
Regarding pituitary hormone deficiencies and their 
influence on mortality, empirical findings are confounded 
by differences in the diagnostic and hormone substitution 
protocols between different study centers over the 
years. In the present study, we could show that neither 
somatotropic nor gonadotropic deficiency plays any 
role concerning TL. Taking into consideration that there 
is a clear link between TL and mortality, our results do 
not support the association between somatotropic or 
gonadotropic deficiency and higher mortality, either. 
Indeed, previous data suggest that GH-deficient patients 
are not at increased risk of death compared to those 
with intact GH secretion (32, 34). However, concerning 
gonadotropic deficiency, data on mortality rates have 
been inconsistent. According to at least one study, 
gonadotropin-deficient patients showed higher mortality, 
an association that remained significant only for men 
after adjustment for dysfunction of other pituitary axes 
and sub-analysis of gonadotropin deficiency according to 
sex (34). However, Ntali et al. (2016) could not confirm 
that unsubstituted gonadotropic deficiency poses a risk 
for mortality.
In the present study, we clearly demonstrated 
that NFPA patients with adrenal insufficiency under 
hydrocortisone substitution did not show shorter 
telomere compared to those with intact corticotropic axis. 
Our results are in accordance with data presenting that 
adrenal deficiency per se is no risk for increased mortality 
when patients are treated with lower dose (up to 20 mg) 
of hydrocortisone (19, 32). Here we show, for the first 
Table 3 Regression analysis of determinants of telomere length in NFPA patients.
Determinant variables
Telomere length (TL)
β P (variable) Adjusted R2 P (model)
Block 1 0.22 <0.001
 Gender 0.042 0.812
 Ageb 0.465 0.005
 BMIb −0.224 0.206
Block 2a 0.429 <0.001
 Gender −0.231 0.2
 Ageb 0.297 0.051
 BMIb −0.429 0.015
 Number of antihypertensive drugs 0.404 0.014
 Daily total HC dose 0.377 0.018
Multiple imputation was used to fill in missing values based on the confirmation that the missing pattern was completely at random. Five complete 
datasets were created, to compensate for the uncertainty caused by missing values. Subsequently, linear regression modeling was performed on each 
dataset, and the regression coefficients of the five models were pooled.
aBlock 1 + diabetes mellitus type 2, HbA1c, arterial hypertension, number of antihypertensive drugs, systolic blood pressure, waist circumference, total 
leucocyte count, current statin use + daily total HC dose; blogarithmized.
β, standardized beta coefficient.
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Figure 2
Telomere length in NFPA depends on the dose of glucocorticoid 
replacement therapy. Correlation of adjusted pPCR values (Ct) with daily 
total hydrocortisone dose in NFPA patients with adrenal insufficiency 
(n = 52). Note, higher Cts are indicative of shorter telomeres. Pearson 
correlation: ß = 0.060, P = 0.091. Ct, threshold cycle.
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time that the dose of daily hydrocortisone substitution 
is linked to TL in NFPA and that patients with a higher 
daily hydrocortisone dose (above 20 mg) presented 
with shorter telomeres. Our findings are in agreement 
with recent data showing increased overall mortality in 
patients with NFPA on higher glucocorticoid replacement. 
Mortality risk in the study of Hammarstrand et al. (2017) 
was higher for patients receiving a daily hydrocortisone 
dose of more than 20 mg compared to subjects with 
daily hydrocortisone doses of ≤20 mg, to patients 
without glucocorticoid replacement and to the general 
population (35).
Moreover, our results are in accordance with studies 
that clearly associate hypercortisolism as in Cushing’s 
syndrome with shorter telomeres (14) and demonstrate 
that patients with active Cushing’s syndrome have shorter 
TL than those patients who underwent successful therapy 
of hypercortisolism (36). Furthermore, TL has been 
evaluated in other conditions with increased endogenous 
cortisol such as chronic stress exposure and post-traumatic 
stress disorder (37). Shorter TL has been reported for 
both neuropsychiatric conditions, notwithstanding the 
influence of their complex interactions with other chronic 
diseases on telomere dynamics (37).
In line with those in vivo findings are studies 
showing that exposure to high hydrocortisone levels in 
vitro results in a 50% reduction of telomerase activity in 
T-lymphocytes (38, 39), clearly suggesting a direct effect 
of cortisol on TL. However, the underlying mechanism 
of how high hydrocortisone doses induce telomere 
shortening remains unresolved. Hypercortisolism seems 
to contribute to premature aging by inducing accelerated 
telomere shortening, which might be an explanation for 
persistent high morbidity and other clinical consequences 
associated with Cushing’s disease, even years after 
successful treatment for hypercortisolism.
This study has a few limitations. On the one hand, 
our control group was chosen from a bigger collective 
of controls after excluding patients with anxiety and 
depression. We addressed this problem by matching 
patients post hoc with the appropriate controls. The 
two groups were matched for the known possible 
confounding factors, i.e., age, gender and smoking status. 
However, presence of metabolic diseases in controls was 
only available by self-report, and are therefore likely 
to be underreported. Other confounding factors such 
as endogenous glucocorticoid exposure could not be 
excluded in this control group.
As for any cross-sectional study, causality cannot be 
inferred. Herein, future studies, beyond the scope of this 
study, need to address causality using, e.g., cortisol-treated 
NFPA patient cells. However, the discussed limitations are 
much more likely to have led to an underestimation of our 
effect sizes than to create false-positive findings. Finally, it 
might be of interest to see, if TL in this particular patient 
group is indeed predictive for increased mortality.
In summary, we demonstrated for the first time 
a significant difference between the TL of patients 
with NFPA and controls. Moreover, we showed a clear 
association of higher hydrocortisone doses with shorter 
TL in these patients, which further underlines the great 
importance of a balanced and adjusted glucocorticoid 
replacement therapy in NFPA patients.
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